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Introduction. The UK Royal College of Pathologists (RCPath) Thy terminology is an internationally 
recognised system for reporting thyroid fine-needle aspiration. The terminology has been used 
throughout the United Kingdom and Ireland, in some parts of Italy and Switzerland, and elsewhere in 
the world. There is no systematic review of the literature which specifically addresses the use of the 
non-diagnostic for cytological diagnosis-Thy1/Thy 1c category in the UK RCPath terminology. 
Methods. A comprehensive literature search of online databases was conducted in October 2019 
specifically examining overall reported rates of Thy1 and Thy1c in aspirates classified according to 
the UK Thy terminology.  
Results. 25 articles were identified showing a Thy1 rate of 13.4% (2540/18920). The studies were 
then stratified according to whether or not the patients underwent rapid on-site assessment (ROSE). 
6.0% (353/5841; range 3.0-10.9%) of ROSE aspirates were Thy1 whereas 18.5% (2072/11204; range 
7.9-43.3%) of non-ROSE patients were Thy1; (p<0.05). Three studies from 2016 reported Thy1c rates 
of 5.4%, 6.5% and 10.6% respectively, implying Thy1 rates excluding Thy1c aspirates of 20.9%, 8.7% 
and 12.7% respectively. 
Conclusion. This systematic review of the literature shows relatively high rates of aspirates non-
diagnostic for cytological diagnosis-Thy1 in the peer-reviewed published literature using the UK 
terminology. Utilisation of ROSE appears to produce lower rates of Thy1 aspirates and ROSE should 
be considered if rates of non-diagnostic for cytological diagnosis-Thy1/Thy 1c are high. 









The UK Thy terminology for reporting thyroid FNAC cytology is a standardised reporting terminology 
for thyroid fine-needle aspiration cytology (FNAC). The terminology evolved from pre-existing 
international1 and UK terminology systems for reporting thyroid FNAC2, 3 following the publication of 
the 2002 British Thyroid Association (BTA)/Royal College of Physicians of London Guidelines for the 
Management of Thyroid Cancer in Adults4, the second edition in 20075 and the third edition in 20146. 
In 2007 Bethesda National Cancer Institute Thyroid Fine Needle Aspiration (FNAC) State of the 
Science Conference took place7 and in 2009 The UK Royal College of Pathologists (RCPath) 
published the first edition of the RCPath Thy terminology8 which was revised in 20169. The latest 
2016 RCPath Thy terminology guidance has five major categories, namely the Thy1, Non-diagnostic 
for cytological diagnosis; Thy1c, Non-diagnostic for cytological diagnosis – cystic lesion; Thy2, Non-
neoplastic; Thy2c, Non-neoplastic – cystic lesion;  Thy3a, Neoplasm possible – atypia / non-
diagnostic; Thy3f, Neoplasm possible, suggestive of a  follicular neoplasm; Thy4, Suspicious of 
malignancy and Thy5, Malignant9. The non-diagnostic for cytological diagnosis category Thy1/Thy1c 
is the default diagnosis if a given sample is not of adequate epithelial cellularity or if the clinical setting 
suggests that the aspirate is not representative of the lesion. The purpose of this literature systematic 
review was to examine the peer-reviewed published literature to date utilising the UK RCPath Thy 
terminology to assess the published rates of Thy1 aspiration in the peer-reviewed literature, to identify 
specific patterns or trends and to ascertain the underlying reasons for Thy 1 aspirates. 
 
Material and Methods  
The UK RCPath Terminology 
The 2016 UK RCPath terminology diagnostic criteria states that solid lesions which are  adequate for 
diagnosis should have at least six groups of thyroid follicular epithelial cells across all the submitted 
slides, each with at least 10 well visualised epithelial cells9. For Thy1 non-diagnostic for cytological 
diagnosis the RCPath guidance requires that the reason for an aspirate being non-diagnostic for 
cytological diagnosis-Thy1 should be described in the cytology report, e.g. a sample that comprises 
entirely blood or so heavily bloodstained that epithelial cells or colloid cannot be visualized, samples 
that are acellular, or that have too low follicular epithelial cellularity to allow diagnosis not reaching the 
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cellular adequacy criterion, or aspirates which are technically unable to be evaluated, e.g. poorly 
spread, delayed air drying or fixation artefact, prominent crush artefact, or cells trapped in fibrin. 
There is a separate category for thyroid cysts, Thy 1c. These are cystic lesion fluid specimens which 
do not reach the follicular epithelial cell adequacy criterion and which contain mostly macrophages but 
without abundant colloid. The UK RCPath guidance suggests that cystic thyroid aspirates can be 
reported as ‘the sample is in keeping with fluid from a cyst but there are no epithelial cells or colloid to 
confirm cyst type’9 and comments that there is a recognised risk of non-representative sampling 
especially in cystic papillary thyroid carcinomas. The RCPath guidance emphasises that it is important 
not to offer false reassurance on suboptimal epithelial cellularity, but equally recommends not to 
overstate the risk of malignancy in such cases, and suggesting careful assessment possibly with 
multidisciplinary discussion. The RCPath guidance aligns with The Bethesda System for Reporting 
Thyroid Cytology (TBSRTC) and other international reporting systems for reporting thyroid FNAC 
cytology, see table 17.  
 
Search strategy 
A comprehensive literature search was conducted using the online databases; Pubmed/MEDLINE, 
ScopusTM and ISI Web of KnowledgeTM. The search aimed to find original peer reviewed studies 
describing the rates of Thy1 aspirates among nodules cytologically classified according to the RCPath 
‘Thy’ system. A combination of the search subject terms (‘thyroid’ &, ‘cytology’ & ‘Thy’) was applied. A 
publication date starting limit of 2002 was applied as the first edition of the British Thyroid Association 
guidance was published in 20024. The search was updated to October 16th, 2019 and no language 
restrictions were used. This approach identified a large number of studies; Pubmed/MEDLINE (91), 
ScopusTM (58) and ISI Web of Science (44)TM. To expand the search, references in the retrieved 
articles were also screened to identify additional studies.  
 
Study selection 
The study inclusion criterion was peer-reviewed original articles reporting thyroid nodules undergoing 
FNAC and cytologically classified according to either the British Thyroid Association Guidance 4, 5  or 
the first8 or second editions9 of The RCPath Guidance on the Reporting of Thyroid Cytology. Dr Poller 
reviewed the titles and abstracts of the retrieved articles applying the study selection criteria and then 
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all authors independently reviewed the full-text of the remaining articles.  Articles or audits available 
online but not published in peer-reviewed journals were excluded. Articles with overlapping patient or 
nodule data and case reports were not considered including patients undergoing rapid on-site 
assessment (ROSE) in one study where there was only one patient with a single Thy 1 aspirate in the 
group of patients undergoing ROSE 10.  
 
Data extraction  
For each included study, the following information was extracted independently in a piloted form: 1) 
study data (authors, year and journal of publication, country of origin, period of patient accrual); 2) 
number of cases in Thy 1 category; and 3) number of cystic cases in the Thy1c category if this was 
documented. Data was cross-checked, and any discrepancies were discussed and mutually resolved.  
 
Statistics.  
Cross tabulation chi-square was performed using Statistica 13.2, (formerly Dell Corporation, now 





In total 25 studies were identified. The publication dates ranged from 2009 to 2018 although patients 
were accrued from earlier time periods starting at the earliest in year 2000. In these 25 studies the 
total number of fine needle aspirates was 18,920 and the overall number of Thy1 aspirates reported 
was 2540 (13.4%); the range of Thy1 percentages in the individual studies was 3.0%-43.3%. In three 
studies (Gill et al. 201611, Glynn et al. 201612 and Parkinson et al. 201613) it was possible to calculate 
number and/or percentage of Thy1c cystic aspirates. In the Gill et al. study11 the percentage of Thy1c 
was 5.4%, in  Glynn et al. 6.5% 12 and in Parkinson et al.10.6% 13. These results are tabulated in table 
2. It can be seen that exclusion of Thy1c cystic lesions does have an impact on Thy1 rates. If Thy1c 
cystic lesions are excluded according to the published literature the rate of Thy1 aspirates falls; in Gill 
et al. from 26.3% to 20.9 %11, in Glynn et al. from 15.2% to 8.7%%12 and in Parkinson et al. from 23.3% 
to 12.7%.13 
The published literature was then reviewed to assess whether rapid on-site evaluation (ROSE) 
appeared to have any impact on Thy 1 aspiration rates. This literature review relied on the authors’ 
methodology as published in the relevant articles. Of the 25 studies10-34, 22 indicated whether or not 
ROSE was undertaken. If ROSE was not specifically mentioned in the methods section or elsewhere 
in the article it was assumed that ROSE was not undertaken. In three studies;  Agarwal et al.14, Lobo 
et al.15 and Mehannah et al.16 although ROSE was undertaken for some patients it was impossible to 
be certain of the exact numbers of patients undergoing ROSE and those that did not and so these 
three articles were excluded from further analysis. Data from Sharma et al.24 is detailed in both Tables 
3 and 4 as some patients underwent ROSE and some did not. Thyroid FNA patients undergoing 
ROSE assessment were excluded in one further article, Breeze et al.10 as there was only one Thy 1 
case in the ROSE patient subgroup.  
Table 3 shows the results for the 6 studies with patients undergoing ROSE FNA’s. In 6 published 
studies where ROSE was undertaken and reported using Thy terminology ROSE was undertaken by 
cytopathologists in three; Mihai et al.17 Kelly et al.33 and Khalil et al.34. In Sharma et al.26 and Brophy 
et al.27 ROSE was undertaken by biomedical scientists/cytotechnologists, and in Deandrea et al. the 
ROSE practitioners were not stated19. There were 353 of 5841 (6.0%) Thy1 aspirates in patients 
undergoing ROSE compared with 2072 (18.5%) Thy1 aspirates out of a total of 11204 FNAs for 
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patients that did not (Table 4). The rate of Thy1 aspirations for patients undergoing ROSE was much 




This systematic review of the published literature shows wide variation in rates of Thy1 aspirates for 
thyroid FNAs reported using The British Thyroid Association and The UK Royal College of 
Pathologists Thy terminology. It also shows that the use of the ‘Thy 1c’ category for cystic lesions as 
suggested in 2016 in the second edition of The Royal College of Pathologists Guidance on the 
Reporting of Thyroid Cytology Specimens does appear to have positively impacted on reported Thy1 
rates if Thy1c aspirates are excluded.11-13 The published literature shows an effect on Thy1 rates with 
utilisation of ROSE. Centres that utilise ROSE appear to have lower rates for Thy1 aspirates than 
those that do not. 
 
The process involved in ROSE, an assessment which is undertaken by a biomedical 
scientist/cytotechnologist or by a qualified cytopathologist is that immediate feedback is given to the 
aspirator, not only on the quality of the sample, the cellularity and the need for re-aspiration, but also 
information may be given to the clinician and patient with a provisional diagnosis if a cytopathologist 
undertakes ROSE. A cytopathologist undertaking ROSE in combination with the sonographer or 
radiologist will have far more clinical information available than a cytopathologist situated remotely 
within a laboratory reporting aspirates received in the laboratory with only clinical information available 
from either the cytopathology clinical request form, and/or from reference to the archived images of 
the ultrasound of lesion(s) and the electronic patient record. It is therefore not surprising that ROSE 
whether undertaken by biomedical scientists or by cytopathologists tends to produce lower rates of 
Thy1 aspirates for thyroid FNA patients than for patients that do not undergo ROSE.  
In this systematic review it was impossible to compare the use of ultrasound versus freehand FNA 
aspiration as most articles do not separately report the number of patients undergoing ultrasound 
FNA as compared to freehand FNA. However from 2010 onwards the majority if not all of patients 
would almost certainly have had fine-needle aspirates taken under ultrasound guidance as this 
appears to be the standard practice for most thyroid FNA’s received in laboratories in the United 
Kingdom and in the other developed countries. 
 
Some centres which undertake thyroid FNA are able to produce acceptable results without the use of 
ROSE. This is well documented in the literature.  Witt and Schmidt in a review and meta-analysis of 8 
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studies of thyroid FNA showed an average thyroid FNA adequacy rate without ROSE of 83% 
compared to 92% with ROSE, although the impact of ROSE depended heavily on the initial 
inadequacy rate35. It cannot be argued therefore that ROSE is essential to providing a high quality fine 
needle aspiration service with low rates for Thy1. The three centres from the UK that reported rates 
for Thy 1c aspirates do not undertake ROSE including one large-volume centre, Newcastle11-13. 
Centres that do not utilise ROSE will require good training in neck ultrasound to ensure nodule 
selection is clinically appropriate and to avoid unnecessary sampling, excellent cytopathology support 
with close communication between the imager/aspirator and the cytopathologist, and high volumes of 
neck FNA to provide familiarity with diagnostically challenging nodules to ensure familiarity with and to 
obtain good quality cytology samples from difficult cases. Given however the high published Thy1 
rates for thyroid FNA, and also unpublished data from a recent UK Endocrine Pathology Society 8 
centre national audit showing similar high rates for Thy 1 aspirates, achieving acceptable Thy1 rates 
appears to be challenging and difficult without wide adoption of ROSE. Some centres overseas report 
rates of TBSRTC category 1/non-diagnostic thyroid FNA (equivalent to the UK Thy1) below 5%. 
These centres with very low non-diagnostic rates for thyroid FNA undertake cytopathologist ROSE 
with immediate reporting in the clinic or ultrasound room36 or cytopathologists may take their own 
ultrasound guided FNA’s37, 38. This is also the experience of some centres in the UK, with Guy’s and 
St Thomas’s Hospital in London showing rates of inadequate head and neck/thyroid FNA of 6.5% with 
use of ROSE39. 
Meta-analyses of TBSRTC in Western patients showed a pooled non-diagnostic FNA rate of 12.9%40 
and for Asian patients 12.2%41 although neither meta-analysis stratified patients according to ROSE 
utilization. A meta-analysis of the risk of malignancy (ROM) for patients with preoperative FNAC 
classified according to the UK Thy terminology showed comparable results to meta-analyses of other 
internationally recognised reporting terminologies for pooled risk of malignancy for surgically excised 
nodules. The results for pooled ROM were Thy 1 12%,  Thy 2 5%,  Thy 3 22%, Thy 3a 25%, Thy 3f 
31%, Thy 4 79%, and Thy 5 98%42. Hence the performance of the UK Thy terminology appears 
similar to TBSRTC and other terminologies, although the range of reported Thy 1 rates in the 





In undertaking this sort of systematic review it is difficult to make definitive recommendations as the 
case mix and clinical settings vary. In another widely used thyroid cytology reporting system, the 
TBSRTC, the non-diagnostic rate shows wide variability among centres (1.8%-23.6%), with an overall 
value of 12.9%40. In the authors’ opinion there could be a minimum acceptable rate for Thy1 
aspiration excluding Thy 1c cystic lesions of no more than 10% to 15%. This could be achievable in a 
UK setting if the UK National Health Service implemented the recent recommendations of The Royal 
College of Pathologists Tissue Pathways for Diagnostic Cytopathology43 which recommend rapid on-
site assessment for fine-needle aspiration. Implementation of ROSE for ultrasound guided thyroid 
FNA could be cost-effective; cost neutral according to the costings of an economic modelling exercise 
undertaken previously44. Part of the issue in the UK setting is that there is no nationally inter-
professionally agreed maximum acceptable rate for Thy1 aspirates and that case-mix; the mix of 
cystic and solid lesions undergoing aspiration may vary as may local resources, training, expertise 
and facilities. The Royal College of Radiologists in an audit template published on the Royal College 
of Radiologists website makes a recommendation of a minimum adequacy criterion of 70% for thyroid 
FNA45. In the authors’ opinion this is undemanding and could be revised upwards to at least 85%, 
corresponding to an overall Thy1 rate excluding Thy 1c aspirates of 15% or lower. The practicalities of 
implementation of rapid on-site assessment for thyroid FNA in conjunction with thyroid and head and 
neck ultrasound clinics needs further discussion and evaluation within the UK setting but the 
published evidence from this systematic review of the literature suggests that implementation of rapid 
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Table 1 Internationally used terminology systems for Thyroid FNAC Cytology 









































Normal or benign 
Thy3a 
Neoplasm 























































































Total Thy1 % Thy 1 % Thy 1c 
if stated 
Mihai et al. 17 Jan 2000- 
Dec 2007 
2009 UK 2809 166 5.9  
Tysome et al. 18 Nov 2005- 
Dec 2007 
2009 UK 520 57 11.0  
Agarwal et al. 14 2006 2009 UK 230 18 7.8  
Deandrea et al. 19 2000-2008 2010 Italy 927 51 5.5  
Lobo et al. 15 Jan 2008- 
Aug 2010 
2011 UK 873 33 3.8  
Raggiunti et al. 20 Oct 2009- 
May 2010 
2011 Italy 617 50 8.1  
Maqbali et al. 21 Mar 2005- 
Sept 2010 
2012 UK 1657 264 15.9  
Burgess et al. 22 Jan 2011- 
June 2011 
2013 UK 184 37 20.0  
Mehanna et al. 16 Nov 2008- 
May 2012 
2013 Ireland 765 63 8.2  
Breeze et al. 10 2012 2014 UK 76 20 26.3  
Poller et al. 23 May 2013- 
Jan 2014 
2014 UK 207 50 24.1  
Doddi et al. 24 Jul 2006- 
Jul 2011 
2015 UK 621 269 43.3  
Sharma et al. 25 Aug 2012- 
Feb 2013 
2015 UK 292 74 25.3  
Sharma et al. 26 Jan 2010- 
Dec 2014 
2015 India 945 75 7.9  
Brophy et al. 27 Jan 2011- 
Dec 2013 
2015 Ireland 1032 80 7.7  
Sakai et al. 28 Sept 2011- 
Dec 2013 
2016 UK 66 14 21.2  
Gill et al. 11 Not stated 2016 UK 355 93 26.3 5.4 
Glynn et al. 12 Jul 2008- 
Jul 2011 
2016 UK 413 63 15.2 6.5 
Parkinson et al. 13 Jan 2008- 
Dec 2014 
2017 UK 2329 544 23.3 10.6 




269 111 41.3  
Giusti et al. 30 Jan 2011- 
Dec 2014 
2017 Italy 1932 193 10.0  
Kavanagh et al. 31 Jul 2006- 
Mar 2013 
2017 Ireland 724 156 21.5  
Kelly et al. 33 2008-2012 2017 Ireland 293 25 8.5  
Liu et al. 32 Aug 2014- 
May 2015 
2017 UK 96 13 13.0  
Khalil et al. 34 Not stated 2018 UAE 688 21 3.0  









 Total FNA Total 
Thy1 
Thy1 % ROSE 
Practitioner(s) 
Mihai et al.17 2009 UK 2809 166 5.9 Pathologist 
Deandrea et al.19 2009 Italy 927 51 5.5 Not stated 
Sharma et al.25 2010 UK 92 10 10.9 Biomedical Scientist 
Brophy et al.27 2015 Ireland 1032 80 7.7 Biomedical Scientist 
Kelly et al.33 2015 Ireland 293 25 8.5 Pathologist 
Khalil et al.34 2017 UAE 688 21 3.0 Pathologist 















Total Thy1 % Thy 1 % Thy1c 
if stated 
Tysome et al. 18 2009 UK 520 57 11.0  
Raggiunti et al.20 2011 Italy 617 50 8.1  
Maqbali et al. 21 2012 UK 1657 264 15.9  
Burgess et al. 22 2013 UK 184 37 20.0  
Breeze et al. 10 2014 UK 69 19 27.5  
Poller et al. 23 2014 UK 207 50 24.1  
Doddi et al. 24 2015 UK 621 269 43.3  
Sharma et al. 25 2015 UK 200 64 32.0  
Sharma et al. 26 2015 India 945 75 7.9  
Sakai et al. 28 2015 UK 66 14 21.2  
Gill et al. 11 2015 UK 355 93 26.2 5.4 
Glynn et al. 12 2016 UK 413 63 15.2 6.5 
Parkinson et al. 13 2016 UK 2329 544 23.3 10.6 
Musa et al. 29 2017 Saudi 
Arabia 
269 111 41.3  
Giusti et al. 30 2017 Italy 1932 193 10.0  
Kavanagh et al. 31 2017 Ireland 724 156 21.5  
Liu et al. 32 2017 UK 96 13 13.0  
TOTALS   11204 2072 18.5  
 
 
